Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Financiere de TubizeCHIX:TUBB 44 EV-to-EBITDA is 86.06 as of Aug. 12, 2026. GuruFocus rates CHIX:TUBB with a GF Score™ of 44/100. The stock has 1 warning sign investors should review. Among 402 Biotechnology companies, Financiere de Tubize ranks worse than 90.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Financiere de Tubize's enterprise value is €8,469.81 Mil.
Financiere de Tubize's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €98.41 Mil. Therefore, Financiere de Tubize's EV-to-EBITDA for today is 86.06.
The historical rank and industry rank for Financiere de Tubize's EV-to-EBITDA or its related term are showing as below:
CHIX:TUBb'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 86.06
Current: 86.06
During the past 13 years, the highest EV-to-EBITDA of Financiere de Tubize was 86.06. The lowest was 0.00. And the median was 0.00.
CHIX:TUBb's EV-to-EBITDA is ranked worse than 90.8% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs CHIX:TUBb: 86.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Financiere de Tubize (CHIX:TUBb) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Financiere de Tubize's PE Ratio (TTM) for today is calculated as:
Financiere de Tubize's share price for today is €235.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Financiere de Tubize's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €2.211.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Financiere de Tubize's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:TUBB vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Financiere de Tubize's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Financiere de Tubize EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Financiere de Tubize's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Financiere de Tubize's EV-to-EBITDA falls into.
Financiere de Tubize's current Enterprise Value is €8,469.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Financiere de Tubize's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €98.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Financiere de Tubize (CHIX:TUBB) has a EV-to-EBITDA of 86.06 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Financiere de Tubize. According to the industry distribution chart, Financiere de Tubize ranks #365 out of 402 companies in the Biotechnology industry, placing it in the top 90.8%.
Is Financiere de Tubize's EV-to-EBITDA too high?
Financiere de Tubize's current EV-to-EBITDA is 86.06. The Biotechnology industry median EV-to-EBITDA is 13.30. Financiere de Tubize's value of 86.06 is 547.1% above this industry median. Based on the distribution chart, Financiere de Tubize ranks #365 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Financiere de Tubize has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Financiere de Tubize's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Financiere de Tubize ranks #365 out of 402 companies for EV-to-EBITDA. This places Financiere de Tubize in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. Financiere de Tubize's value of 86.06 is 547.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Financiere de Tubize's current EV-to-EBITDA of 86.06 is 547.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Financiere de Tubize. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Financiere de Tubize's current EV-to-EBITDA is 86.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Financiere de Tubize stock overvalued right now?
Financiere de Tubize (CHIX:TUBB) has a current EV-to-EBITDA of 86.06. The current EV-to-EBITDA is 86.06 and 547.1% above the Biotechnology industry median of 13.30. Financiere de Tubize's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Financiere de Tubize (CHIX:TUBB), the current EV-to-EBITDA is 86.06 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
44GF Score
Get the complete analysis for CHIX:TUBB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:TUBB has been successfully added to your 
